Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154495331> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2154495331 endingPage "xii" @default.
- W2154495331 startingPage "xi" @default.
- W2154495331 abstract "Mantle cell lymphoma (MCL) and Burkitt lymphoma respond to initial intense therapies, such as hyper-CVAD (hyperfractionated cyclophosphamide/ vincristine/doxorubicin/dexamethasone) alternating with high-dose methotrexate/cytarabine, to which the monoclonal antibody rituximab has recently been added. This report provides an update detailing the long-term outcome when this chemoimmunotherapy regimen is used as first-line therapy for newly diagnosed MCL, de novo Burkitt lymphoma, atypical Burkitt lymphoma, and mature B-cell acute lymphoblastic lymphoma (B-ALL). Ninetyseven patients with de novo MCL and 31 patients with Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL were treated with rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine under different institutional trials approved by the University of Texas M. D. Anderson Cancer Center Institutional Review Board. Overall response rate (RR) for patients with MCL was 97% (complete response [CR]/unconfirmed CR rate, 87%). At a median follow-up of 4.8 months, the 5-year failure-free survival and OS rates were 48% and 65%, respectively. Among patients aged ≤ 65 years, the 5 year failure-free survival was 60%. Patients with blastoid morphology have a 7-year survival rate of 47%. Toxicity was mainly hematologic but significant. Overall RR for patients with Burkitt lymphoma/atypical Burkitt lymphoma/B-ALL was 97% (CR rate, 86%). With a median follow-up of 22 months, the estimated 3-year OS, disease-free survival, and event-free survival rates were 89%, 88%, and 80%, respectively. Rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine is an effective dose-intense chemoimmunotherapy program for untreated MCL, Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL. Toxicity is mainly hematologic and significant, but expected." @default.
- W2154495331 created "2016-06-24" @default.
- W2154495331 creator A5071796883 @default.
- W2154495331 date "2005-04-01" @default.
- W2154495331 modified "2023-09-30" @default.
- W2154495331 title "Multidisciplinary Approach to Lung Cancer" @default.
- W2154495331 doi "https://doi.org/10.1016/j.hoc.2005.02.001" @default.
- W2154495331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15833402" @default.
- W2154495331 hasPublicationYear "2005" @default.
- W2154495331 type Work @default.
- W2154495331 sameAs 2154495331 @default.
- W2154495331 citedByCount "0" @default.
- W2154495331 crossrefType "journal-article" @default.
- W2154495331 hasAuthorship W2154495331A5071796883 @default.
- W2154495331 hasConcept C126322002 @default.
- W2154495331 hasConcept C143998085 @default.
- W2154495331 hasConcept C2776694085 @default.
- W2154495331 hasConcept C2776755627 @default.
- W2154495331 hasConcept C2777525834 @default.
- W2154495331 hasConcept C2778041864 @default.
- W2154495331 hasConcept C2779338263 @default.
- W2154495331 hasConcept C2779429289 @default.
- W2154495331 hasConcept C2780653079 @default.
- W2154495331 hasConcept C2780790343 @default.
- W2154495331 hasConcept C2781413609 @default.
- W2154495331 hasConcept C71924100 @default.
- W2154495331 hasConcept C90924648 @default.
- W2154495331 hasConceptScore W2154495331C126322002 @default.
- W2154495331 hasConceptScore W2154495331C143998085 @default.
- W2154495331 hasConceptScore W2154495331C2776694085 @default.
- W2154495331 hasConceptScore W2154495331C2776755627 @default.
- W2154495331 hasConceptScore W2154495331C2777525834 @default.
- W2154495331 hasConceptScore W2154495331C2778041864 @default.
- W2154495331 hasConceptScore W2154495331C2779338263 @default.
- W2154495331 hasConceptScore W2154495331C2779429289 @default.
- W2154495331 hasConceptScore W2154495331C2780653079 @default.
- W2154495331 hasConceptScore W2154495331C2780790343 @default.
- W2154495331 hasConceptScore W2154495331C2781413609 @default.
- W2154495331 hasConceptScore W2154495331C71924100 @default.
- W2154495331 hasConceptScore W2154495331C90924648 @default.
- W2154495331 hasIssue "2" @default.
- W2154495331 hasLocation W21544953311 @default.
- W2154495331 hasLocation W21544953312 @default.
- W2154495331 hasOpenAccess W2154495331 @default.
- W2154495331 hasPrimaryLocation W21544953311 @default.
- W2154495331 hasRelatedWork W1499275448 @default.
- W2154495331 hasRelatedWork W1971347970 @default.
- W2154495331 hasRelatedWork W2005004376 @default.
- W2154495331 hasRelatedWork W2016341751 @default.
- W2154495331 hasRelatedWork W2057879896 @default.
- W2154495331 hasRelatedWork W2093893201 @default.
- W2154495331 hasRelatedWork W2105351857 @default.
- W2154495331 hasRelatedWork W2112679438 @default.
- W2154495331 hasRelatedWork W2121694206 @default.
- W2154495331 hasRelatedWork W2409484189 @default.
- W2154495331 hasVolume "19" @default.
- W2154495331 isParatext "false" @default.
- W2154495331 isRetracted "false" @default.
- W2154495331 magId "2154495331" @default.
- W2154495331 workType "article" @default.